Literature DB >> 3365647

Primary central nervous system germ cell tumors. Effect of histologic confirmation on radiotherapy.

C R Kersh1, W C Constable, D R Eisert, C A Spaulding, S S Hahn, J M Jenrette, R D Marks.   

Abstract

Primary malignant intracranial germ cell tumors are rare lesions responsible for only 0.5% of all central nervous system (CNS) malignancy. With stereotactic localization these lesions can be safely biopsied, and histologic confirmation will affect the ultimate prognosis. This report is a multi-institutional retrospective analysis of 33 patients diagnosed with a primary CNS germ cell tumor. Tumors in 14 patients (42%) were histologically confirmed (13 germinoma and one embryonal cell carcinoma); 19 patients were treated with a presumptive diagnosis. All patients were irradiated with a dose range of 3950 cGy to 6000 cGy to the primary lesions. Eight patients received craniospinal irradiation, and 25 patients were locally treated. The 5-year actuarial survival for the entire population was 64%. The survival rate in patients with histologic confirmation was 79% versus 53% in the unbiopsied population. Radiation doses greater than 5000 cGy, radiotherapy volume, and age were prognostic factors in determining survival.

Entities:  

Mesh:

Year:  1988        PMID: 3365647     DOI: 10.1002/1097-0142(19880601)61:11<2148::aid-cncr2820611103>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Clinical outcomes of adult patients with primary intracranial germinomas treated with low-dose craniospinal radiotherapy and local boost.

Authors:  M Foote; B-A Millar; A Sahgal; C Ménard; D Payne; W Mason; N Laperriere
Journal:  J Neurooncol       Date:  2010-05-09       Impact factor: 4.130

2.  Predictors of long-term survival following postoperative radiochemotherapy for pathologically confirmed suprasellar germ cell tumors.

Authors:  Lei Huo; Xia Wang; Pamela K Allen; Longyun Wang; Yuping Liao; Zaide Han; Liangfang Shen; Qingsong Tu; Meizuo Zhong; Yan Zhuang; Jing Li; Jidong Hong
Journal:  Mol Clin Oncol       Date:  2014-11-20

3.  Complete disappearance of giant intracranial germinoma after irradiation.

Authors:  N G Rainov; H J Holzhausen; W Burkert
Journal:  Neurosurg Rev       Date:  1995       Impact factor: 3.042

Review 4.  Microsurgical resection of pineal region tumors.

Authors:  Adam M Sonabend; Stephen Bowden; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2016-05-19       Impact factor: 4.130

5.  Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors.

Authors:  Tomohiro Kawaguchi; Toshihiro Kumabe; Masayuki Kanamori; Ryuta Saito; Yoji Yamashita; Yukihiko Sonoda; Mika Watanabe; Teiji Tominaga
Journal:  J Neurooncol       Date:  2011-02-26       Impact factor: 4.130

Review 6.  Surgical strategies for treating patients with pineal region tumors.

Authors:  Jeffrey N Bruce; Alfred T Ogden
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 7.  Current advances in the diagnosis and management of intracranial germ cell tumors.

Authors:  Casilda Balmaceda; Jonathan Finlay
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

8.  Treatment strategy for intracranial primary pure germinoma.

Authors:  Kyu-Won Shim; Eun Kyung Park; Yoon-Ho Lee; Chang-Ok Suh; Jaeho Cho; Joong-Uhn Choi; Dong-Seok Kim
Journal:  Childs Nerv Syst       Date:  2012-09-11       Impact factor: 1.475

9.  Pineal gland tumors: experience from the SEER database.

Authors:  Maysa Al-Hussaini; Iyad Sultan; Najyah Abuirmileh; Imad Jaradat; Ibrahim Qaddoumi
Journal:  J Neurooncol       Date:  2009-04-17       Impact factor: 4.130

10.  Germinoma involving the basal ganglia in children.

Authors:  Tai-Tong Wong; Y W Chen; Wan-Yuo Guo; Kai-Ping Chang; Donald M Ho; Sang-Hue Yen
Journal:  Childs Nerv Syst       Date:  2007-09-29       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.